A new peer-reviewed Perspective in Genomic Psychiatry released on June 25 suggests that laboratory dogs, particularly Beagles, could serve as a critical bridge in the development of autism drugs. The article synthesizes a decade of research findings and proposes that dogs may offer advantages over traditional animal models such as mice and monkeys.
The authors point out that more than ninety percent of candidate autism drugs fail between laboratory testing and human trials. They attribute much of this failure to the limitations of current animal models, which cannot replicate the social behaviors most affected by autism. Mice do not read faces or engage in complex social interactions, while monkeys are costly to maintain and interpret direct human gaze as threatening rather than friendly.
Dr. Siqi Yuan, lead author of the Perspective, said, "Dogs did not simply move in beside us. They co-evolved to understand us. That shared social wiring is exactly what other laboratory species lack, and it is exactly what autism research has been missing." The article highlights studies involving dogs with engineered changes in Shank3—a gene linked to autism in humans—showing that these animals exhibit traits similar to those seen in people with autism. These include reduced social contact, altered sensory responses, and avoidance of eye contact.
Professor Yong Q. Zhang from Hubei University said, "When you place the canine findings beside the human literature, the overlaps are difficult to dismiss. This is not a replacement for mice or monkeys. It is a complement, a third lens that brings the social dimension into focus." The review also references preliminary evidence suggesting some traits can be mitigated using treatments like oxytocin nasal spray or compounds affecting neural activity; however, sample sizes remain small and results are considered early-stage.
The authors acknowledge ethical concerns about using dogs in research due to their close relationship with humans but emphasize adherence to principles such as replacement, reduction, and refinement when designing studies involving animals. Technical challenges also persist: gene editing success rates remain low in dogs compared to other species; some mutations can be lethal; training for brain scans is time-consuming; and neuroscience tools for canine studies lag behind those available for mice.
The paper concludes by calling for interdisciplinary collaboration and improved methods while positioning dogs not just as experimental subjects but as potential translators between human biology and clinical outcomes.
